Peptide
Based Infection Therapeutics Market by Drug (Telaprevir, and Boceprevir),
by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online
Pharmacies) and by Geography - Size, Share, Outlook, and Opportunity Analysis
2018 – 2026
Excessive and inappropriate use
of antibiotics is creating antibiotic resistance among affected population at
present. Therefore, the urge of developing novel therapies in fighting
infections is increasing. A novel, peptide based therapies for treating
infections has offered various advantages in terms of stability, safety,
tolerance, possesses selective nature, effective with broad spectrum of
activities and mechanisms. They also protect the host from pathogenic microbes,
so also referred as host defense peptides.
Peptide Based Infection
Therapeutics Market – Drivers
Increase in number of pipeline
drugs is expected to drive peptide based infection therapeutics market. For
instance, in September 2018, BioAegis Therapeutics Inc. started clinical trials
for Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in
Community-Acquired Pneumonia (CAP), in Australasia and has observed reduced
morbidity and mortality in over 20 infectious and non-infectious disease animal
models.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2185
Furthermore, LA Jolla
Pharmaceutical Company is undergoing phase II clinical trials for LJPC-501, and
is expected to complete study in April 2023. This drug can be used for treating
Septic Shock.
Peptide Based Infection Therapeutics
Market – Restraint
High cost of alternative
techniques in manufacturing of peptide drugs to avoid peptide degradation may
hamper the growth of the market. For instance, According to an article
published in Biomolecule 2017, utilization of techniques such as Liposomes,
PEGylation, need to develop for effective peptide drug delivery have increased
the overall cost of therapy and thus restraint the growth of the market.
Peptide Based Infection Therapeutics
Market – Regional Analysis
On the basis of region, the
Peptide Based Infection Therapeutics Market is segmented into North America,
Latin America, Europe, Asia Pacific, Middle East, and Africa. North America
expected to show higher market attractiveness and domination over other regions
due to new advancements in treatment such as peptide vaccines, and presence of
large number of peptide manufacturing companies. In 2014-2015, AmbioPharm,
Inc., a company of U.S., is manufacturing peptide based antifungals with better
efficacy. This company has also expanded its manufacturing units in America and
China to meet the demands.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/peptide-based-infection-therapeutics-market-2185
Furthermore, high number of
morbidity of infectious diseases is also driving the growth of market in U.S.
For instance, According to World Health Organization (WHO) 2016 statistics, in
U.S., number of new tuberculosis cases were 9,272 and number of new salmonella
cases were 53,850.
Peptide Based Infection
Therapeutics Market – Competitive Landscape
The key players involved in this
market are Vertex Pharmaceuticals Incorporated, Merck & Co., Inc. Parchem
Fine & Specialty Chemicals, AmbioPharm Inc., CoredentPharma International,
GenScript, Sun Pharmaceutical Industries Ltd., Bharat Biotech, and Dr. Reddy’s
Laboratories Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2185
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment